Acute Lymphoblastic Leukemia (ALL) (outsource Genetech) at Chughtai Lab

Acute Lymphoblastic Leukemia (ALL) (outsource Genetech) at Chughtai Lab

Acute Lymphoblastic Leukemia (ALL) is a rapid, aggressive form of cancer affecting the white blood cells, specifically the lymphoid progenitor cells. To provide patients and oncologists with the most precise diagnostic insights, Chughtai Lab offers the specialized Acute Lymphoblastic Leukemia (ALL) (outsource Genetech) panel. This advanced molecular diagnostic test is performed in collaboration with Genetech, a premier molecular genetics reference laboratory. By utilizing state-of-the-art genetic analysis, this test identifies critical chromosomal translocations, gene rearrangements, and molecular mutations that define the specific subtype of ALL. Understanding these genetic markers is paramount for establishing an accurate diagnosis, determining the patient’s prognosis, and designing a highly targeted, personalized therapeutic strategy.

The diagnostic journey for leukemia has evolved far beyond simple microscopic evaluation. While conventional bone marrow morphology and flow cytometry confirm the presence of lymphoblasts, molecular testing via the Acute Lymphoblastic Leukemia (ALL) (outsource Genetech) panel looks deep into the genetic blueprint of the malignant cells. This test employs highly sensitive techniques such as Polymerase Chain Reaction (PCR) and Fluorescence In Situ Hybridization (FISH) to detect specific fusion genes, such as BCR-ABL1, ETV6-RUNX1, and TCF3-PBX1. Identifying these molecular abnormalities allows hematologists to classify the disease according to the World Health Organization (WHO) guidelines, risk-stratify the patient into standard or high-risk categories, and monitor minimal residual disease (MRD) during and after chemotherapy. Chughtai Lab, with its extensive diagnostic network across Pakistan, ensures seamless sample collection, strict cold-chain logistics, and reliable reporting for this critical oncological investigation.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure sample integrity and accurate molecular analysis. Patients undergoing the Acute Lymphoblastic Leukemia (ALL) (outsource Genetech) test should observe the following guidelines:

• Consultation and Documentation: Patients must provide a complete clinical history, including previous hematology reports (CBC, bone marrow biopsy, flow cytometry) and details of any ongoing chemotherapy or targeted treatments.
• Fasting: Routine fasting is generally not required for this molecular test, whether performed on peripheral blood or bone marrow. However, patients should follow any specific dietary instructions provided by their referring hematologist.
• Medication Review: Inform the healthcare provider about all medications, especially anticoagulants (blood thinners) such as aspirin, warfarin, or heparin, as these can affect bleeding times during bone marrow procedures.
• Consent Form: A signed informed consent form for genetic and molecular testing is mandatory before sample collection.
• Hydration: Adequate hydration is recommended prior to the procedure to facilitate blood collection and support overall patient comfort.

During the Procedure

The collection of the specimen for the Acute Lymphoblastic Leukemia (ALL) (outsource Genetech) test can be performed using either peripheral blood or bone marrow aspirate, depending on the clinical scenario and the physician’s recommendation:

• Peripheral Blood Collection: If peripheral blood is used, a trained phlebotomist at Chughtai Lab will perform a standard venipuncture. The skin over a vein in the arm is cleansed with an antiseptic, a tourniquet is applied, and blood is drawn into specialized EDTA (purple top) tubes. The process takes only a few minutes and involves minimal discomfort.
• Bone Marrow Aspiration: If a bone marrow sample is required, the procedure is performed by a qualified hematologist or clinical oncologist in a sterile clinical setting. The patient is positioned comfortably (usually lying on their side or stomach). Local anesthesia is administered to numb the skin and the periosteum of the posterior superior iliac spine (hip bone). A specialized bone marrow needle is inserted, and a small volume of liquid bone marrow is aspirated. Patients may feel a brief, deep pulling or suction sensation during aspiration.
• Sample Handling and Logistics: Once collected, the specimen is meticulously labeled with the patient’s unique identification details. Because this is an outsourced test to Genetech, Chughtai Lab implements strict cold-chain logistics to maintain sample viability at 2-8°C during transit to the specialized molecular laboratory.
• Safety and Comfort: For bone marrow procedures, post-procedure monitoring is conducted to ensure there is no active bleeding or adverse reaction to the local anesthetic. A sterile dressing is applied to the site, and patients are advised on post-procedure care.

When is an Acute Lymphoblastic Leukemia (ALL) (outsource Genetech) Performed?

Initial Diagnosis and Subtyping of Leukemia

When a patient presents with clinical signs suggestive of acute leukemia, such as unexplained cytopenias or circulating blasts, this molecular panel is requested immediately. It helps differentiate B-cell ALL from T-cell ALL and identifies the underlying genetic abnormalities. This classification is vital because different genetic subtypes respond differently to specific chemotherapeutic regimens, making molecular subtyping a cornerstone of modern hematooncology.

Prognostic Stratification

Not all cases of ALL behave the same way; some are highly aggressive, while others have a more favorable prognosis. The detection of specific genetic translocations via the Genetech panel allows clinicians to stratify patients into low, standard, or high-risk groups. For example, the presence of the ETV6-RUNX1 fusion gene is generally associated with a favorable outcome, whereas the BCR-ABL1 translocation indicates a high-risk profile requiring intensive therapeutic interventions.

Targeted Therapy Selection

With the advent of precision medicine, identifying specific molecular targets can dramatically improve survival rates. Patients who test positive for the BCR-ABL1 fusion gene (Philadelphia chromosome-positive ALL) are candidates for targeted tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or ponatinib. This test is essential to identify these patients at the time of diagnosis so that targeted agents can be integrated into their treatment protocol.

Monitoring Minimal Residual Disease (MRD)

During and after chemotherapy, standard microscopic evaluation of bone marrow may show no visible leukemia cells (complete morphological remission). However, subclinical levels of leukemia cells (minimal residual disease) may still persist. The highly sensitive molecular assays provided in this outsourced panel can detect one leukemia cell among tens of thousands of normal cells, allowing oncologists to assess treatment efficacy and predict potential relapses early.

Evaluation of Relapse and Treatment Resistance

If a patient experiences a clinical relapse or fails to respond to standard induction chemotherapy, this molecular panel is repeated. It helps determine if the leukemia cells have acquired new genetic mutations or clonal evolution, which could explain drug resistance. This information is critical for selecting salvage therapies, enrolling patients in clinical trials, or preparing them for an allogeneic stem cell transplant.

What Does an Acute Lymphoblastic Leukemia (ALL) (outsource Genetech) Detect?

This comprehensive molecular diagnostic panel is designed to detect a wide array of clinically significant genetic aberrations, translocations, and molecular markers associated with Acute Lymphoblastic Leukemia. Specifically, the test evaluates and detects:

• BCR-ABL1 [t(9;22)] fusion transcripts (p190 and p210 isoforms)
• ETV6-RUNX1 [t(12;21)] fusion gene
• TCF3-PBX1 [t(1;19)] fusion gene
• KMT2A (MLL) gene rearrangements [t(4;11) and other partner genes]
• IGH-CRLF2 gene rearrangements
• IKZF1 (Ikaros) gene deletions or mutations
• JAK1, JAK2, and JAK3 gene mutations
• IL7R gene mutations
• PAX5 gene alterations and deletions
• CDKN2A/B gene deletions
• TP53 gene mutations and deletions
• NOTCH1 mutations (highly relevant in T-ALL)
• FBXW7 mutations (associated with T-ALL)
• PTEN gene deletions and mutations
• TAL1 gene rearrangements
• LMO1 and LMO2 gene activations
• TLX1 and TLX3 gene overexpressions
• FLT3 gene internal tandem duplications (ITD) or tyrosine kinase domain (TKD) mutations
• NRAS and KRAS codon mutations
• CREBBP gene mutations
• WHSC1L1 gene abnormalities
• EBF1 gene deletions
• BTG1 gene deletions
• SH2B3 gene mutations
• ABL1 kinase domain mutations (in cases of TKI resistance)
• Clonal immunoglobulin (IGH) gene rearrangements for MRD tracking
• Clonal T-cell receptor (TCR) gene rearrangements for MRD tracking
• Ploidy status (hyperdiploidy or hypodiploidy markers)

Turnaround Time and Report Access at Chughtai Lab

Because the Acute Lymphoblastic Leukemia (ALL) (outsource Genetech) test is a highly specialized molecular assay requiring advanced genomic technology, the turnaround time is longer than routine blood tests. Typically, the final comprehensive report is completed within 10 to 14 working days from the date of sample collection. This timeframe ensures that the complex molecular extraction, amplification, and analysis phases are conducted under stringent quality control protocols at Genetech.

Chughtai Lab provides multiple convenient methods for patients and referring oncologists to access these critical diagnostic reports. Once the results are verified by the consultant molecular pathologist, an automated SMS notification is sent to the patient’s registered mobile number. Reports can be viewed, downloaded, and printed directly from the official Chughtai Lab website or through the user-friendly Chughtai Lab mobile application. Additionally, physical copies of the reports can be collected from any Chughtai Lab diagnostic center across Pakistan.

Acute Lymphoblastic Leukemia (ALL) (outsource Genetech) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
BCR-ABL1 [t(9;22)] Fusion	Not Detected (Negative)	Detected (Positive); indicates Philadelphia chromosome-positive ALL, requiring TKI therapy.
ETV6-RUNX1 [t(12;21)] Fusion	Not Detected (Negative)	Detected (Positive); typically associated with a favorable prognosis in pediatric B-ALL.
TCF3-PBX1 [t(1;19)] Fusion	Not Detected (Negative)	Detected (Positive); associated with pre-B-ALL and may require intensive chemotherapy.
KMT2A (MLL) Rearrangements	Not Detected (Negative)	Detected (Positive); common in infant ALL, indicating high-risk disease and poor prognosis.
IKZF1 Gene Status	Wild Type (No Deletion)	IKZF1 Deletion Detected; associated with high relapse rates and resistance to therapy.
CRLF2 Gene Expression	Normal Expression Levels	CRLF2 Overexpression/Rearrangement; associated with Ph-like ALL and poor outcomes.
NOTCH1/FBXW7 Mutations	Not Detected (Negative)	Mutations Detected; highly prevalent in T-cell ALL, guiding specific therapeutic protocols.
Minimal Residual Disease (MRD)	No Clonal Rearrangements Detected	Clonal IGH/TCR Rearrangements Detected; indicates persistent subclinical leukemia cells.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Acute Lymphoblastic Leukemia (ALL) (outsource Genetech)?

• Established Diagnostic Network: Chughtai Lab is one of Pakistan’s most trusted and extensive diagnostic networks, ensuring reliable healthcare services.
• Strategic Collaboration: Partnering with Genetech ensures access to cutting-edge molecular and genetic testing technologies.
• Strict Cold-Chain Management: Specialized logistics guarantee that oncology specimens are transported under optimal temperature conditions to preserve sample integrity.
• Expert Pathologist Oversight: Reports are reviewed and interpreted by highly qualified hematopathologists and molecular geneticists.
• Convenient Report Access: Patients and oncologists can easily access reports online via the website, email, or the Chughtai Lab mobile app.
• Home Sample Collection: Chughtai Lab offers professional home sample collection services for blood samples, ensuring patient comfort during difficult clinical times.
• State-of-the-Art Facilities: Utilizing modern diagnostic equipment and adhering to international quality control standards.
• Compassionate Patient Care: Dedicated support staff and clinical teams committed to providing a seamless, stress-free diagnostic experience for cancer patients.